Chantal Adani

Prof. Chantal Adani

Ocular Immunology Unit, Azienda USL-IRCCS, Reggio Emilia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBElena Bolletta
Elena Bolletta
DIDanilo Iannetta
Danilo Iannetta
VMvalentina mastrofilippo
valentina mastrofilippo
Luca De SimoneLuca De Simone
Luca De Simone
FGFabrizio Gozzi
Fabrizio Gozzi
Luca CiminoLuca Cimino
Luca Cimino
Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age of 49.8 years (range 18–83 years). The cases reported were three herpetic keratitis, two anterior scleritis, five anterior uveitis (AU), three toxoplasma retinochoroiditis, two Vogt-Koyanagi-Harada (VKH) disease reactivations, two pars planitis, two retinal vasculitis, one bilateral panuveitis in new-onset Behçet’s disease, three multiple evanescent white dot syndromes (MEWDS), one acute macular neuroretinopathy (AMN), five retinal vein occlusions (RVO), one non-arteritic ischemic optic neuropathy (NAION), three activations of quiescent choroidal neovascularization (CNV) secondary to myopia or uveitis, and one central serous chorioretinopathy (CSCR). Mean time between vaccination and ocular complication onset was 9.4 days (range 1–30 days). Twenty-three cases occurred after Pfizer-BioNTech vaccination (BNT162b2 mRNA), 7 after Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19), 3 after ModernaTX vaccination (mRNA-1273), and 1 after Janssen Johnson & Johnson vaccine (Ad26.COV2). Uveitis and other ocular complications may develop after the administration of COVID-19 vaccine.

1 November 2017 in Ophthalmology
Verified
Journal Article
Closed access
AIAlessandro Invernizzi
Alessandro Invernizzi
SMSylvia Marchi
Sylvia Marchi
RARaffaella Aldigeri
Raffaella Aldigeri
VMvalentina mastrofilippo
valentina mastrofilippo
FVFabiana Viscogliosi
Fabiana Viscogliosi
Luca CiminoLuca Cimino
Luca Cimino

23 July 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
FGFabrizio Gozzi
Fabrizio Gozzi
MBMarco Bertolini
Marco Bertolini
PGPietro Gentile
Pietro Gentile
LVLaura Verzellesi
Laura Verzellesi
VTValeria Trojani
Valeria Trojani
Luca CiminoLuca Cimino
Luca Cimino
Anterior segment optical coherence tomography (AS-OCT) allows the explore not only the anterior chamber but also the front part of the vitreous cavity. Our cross-sectional single-centre study investigated whether AS-OCT can distinguish between vitreous involvement due to vitreoretinal lymphoma (VRL) and vitritis in uveitis. We studied AS-OCT images from 28 patients (11 with biopsy-proven VRL and 17 with differential diagnosis uveitis) using publicly available radiomics software written in MATLAB. Patients were divided into two balanced groups: training and testing. Overall, 3260/3705 (88%) AS-OCT images met our defined quality criteria, making them eligible for analysis. We studied five different sets of grey-level samplings (16, 32, 64, 128, and 256 levels), finding that 128 grey levels performed the best. We selected the five most effective radiomic features ranked by the ability to predict the class (VRL or uveitis). We built a classification model using the xgboost python function; through our model, 87% of eyes were correctly diagnosed as VRL or uveitis, regardless of exam technique or lens status. Areas under the receiver operating characteristic curves (AUC) in the 128 grey-level model were 0.95 [CI 0.94, 0.96] and 0.84 for training and testing datasets, respectively. This preliminary retrospective study highlights how AS-OCT can support ophthalmologists when there is clinical suspicion of VRL.

6 October 2020 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
Luca De SimoneLuca De Simone
Luca De Simone
AIAlessandro Invernizzi
Alessandro Invernizzi
RARaffaella Aldigeri
Raffaella Aldigeri
VMValentina Mastrofilippo
Valentina Mastrofilippo
CMChiara Marvisi
Chiara Marvisi
Luca CiminoLuca Cimino
Luca Cimino
To report long term results of biologic treatment of severe and refractory Behçet’s uveitis (BU) choosing a different biologic agent according to the uveitis clinical features.Retrospective cohort ...

1 April 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
EBElena Bolletta
Elena Bolletta
FGFabrizio Gozzi
Fabrizio Gozzi
VMvalentina mastrofilippo
valentina mastrofilippo
NPNicolò Pipitone
Nicolò Pipitone
Luca De SimoneLuca De Simone
Luca De Simone
Luca CiminoLuca Cimino
Luca Cimino
Purpose: To evaluate the efficacy of Rituximab (RTX) therapy in patients affected by Vogt-Koyanagi-Harada (VKH) disease poorly controlled by traditional immunosuppressive treatment. Methods: Retrospective case series of recurrent VKH uveitis treated with intravenous RTX between January 2019 and November 2020. All patients were treated with intravenous RTX and underwent complete ophthalmic examination, best-corrected visual acuity (BCVA), fundus photography, subfoveal choroidal thickness (SFCT) measurement on enhanced depth imaging optical-coherence tomography (EDI-OCT), fluorescein, and indocyanine green angiography. Results: Five patients were included. All patients received at least 3 RTX infusions. Mean BCVA improved from 20/32 Snellen equivalent at baseline before RTX treatment to 20/28 Snellen equivalent (p = .008). Mean SFCT on EDI-OCT showed a reduction from 564.4 µm(SD = 176.2) to 280.0 µm(SD = 140.4) (p = .015). Follow-up ranged from 12 to 21 months, with a mean of 18.2 ± 3.7 months. Conclusions: In these case series, RTX was effective in VHK disease poorly controlled by traditional immunosuppressive treatment.

18 September 2020 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
AIAlfonso Iovieno
Alfonso Iovieno
MCMarco Coassin
Marco Coassin
FVFabiana Viscogliosi
Fabiana Viscogliosi
CAChantal Adani
Chantal Adani
Luca CiminoLuca Cimino
Luca Cimino
LFLuigi Fontana
Luigi Fontana
Epstein-Barr Virus (EBV) has been previously reported to cause rare occurrence of mostly epithelial and nummular keratitis. We hereby report two patients developing bilateral peripheral deep interstitial keratitis following EBV-related infectious mononucleosis (IM). Two female adolescents presented with findings of chronic relapsing posterior interstitial keratitis with neovascularisation mostly located in the superior and inferior peripheral cornea, in absence of signs of anterior uveitis. The disease presented months after the occurrence of IM. Other etiologies of interstitial keratitis were excluded. EBV DNA could not be detected in the aqueous humor of both patients. The patients responded promptly to topical corticosteroids, with multiple recurrences reported in one case. EBV-induced IM can cause bilateral peripheral interstitial keratitis with delayed onset. Progressive relapsing course of the keratitis can be observed.